Registrational

BOSTON and LONDON, July 10, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today…

PHILADELPHIA and VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage immunotherapy company driven to fight cancer and…

Topline data expected mid-2023Potential Biologics License Application (BLA) submission end of 2023 HOUSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late clinical-stage oncology company…

•   LIBRA trial designed to support registration in China•   Topline results expected in the fourth quarter of 2023 SHANGHAI and PRINCETON, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company…

Topline data from UPLIFT expected in mid-2023Targeting potential Biologics License Application (BLA) submission by the end of 2023 CAMBRIDGE, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a…

SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the initiation of its Phase 3…

Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically significant and clinically meaningful…

--the study reached its primary endpoint(VV116 was statistically superior) and secondary efficacy endpoint --VV116 has a favorable safety profile and fewer adverse events than PAXLOVID SHANGHAI, China, May 25, 2022 (GLOBE NEWSWIRE) --…

NEW YORK and SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental…

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the…